Q2 2026 Elutia Inc Earnings Call Transcript
Key Points
- Elutia Inc (ELUT) secured up to $26 million in additional capital without an equity offering, including a $15 million credit facility from Avenue Capital Group, ensuring funding through the NXT41X clearance and full commercial launch in 2028.
- A blinded survey of 50 board-certified plastic and reconstructive surgeons showed 96% interest in adopting NXT41X, 92% willingness to champion it at hospital value analysis committees, and 100% would use it for high-risk patients, indicating strong market demand.
- The company is advancing regulatory milestones on schedule, with NXT-41 clearance expected in Q4 2026 and NXT-41X clearance in H1 2027, following a productive FDA meeting.
- Manufacturing readiness is progressing, with the automated drug coating system qualified for commercial production at scale, targeting gross margins greater than 80% and capacity for at least $300 million in revenue at launch.
- Elutia Inc (ELUT) is becoming more focused by divesting non-core assets, including the SimpliDerm sale for up to $11 million and the cardiovascular process, concentrating resources on the high-value NXT41X opportunity.
- The company's financial position is strengthened with total cash sources projected at $54 million, including the $8 million escrow from Boston Scientific and additional funds from the SimpliDerm deal, providing runway through at least 2028.
- Total net sales for Q2 2026 declined to $2.4 million from $2.7 million in the prior year, driven by a $0.7 million drop in SimpliDerm sales due to a production disruption at its contract manufacturer.
- Adjusted EBITDA loss widened to $4.6 million in Q2 2026 from $3.0 million a year ago, primarily due to increased R&D expenses supporting NXT41 and NXT41X development.
- The company continues to incur operating losses, with a net loss from continuing operations of $7.6 million in Q2 2026, slightly worse than the $7.1 million loss in the prior year period.
- The divestiture of SimpliDerm and potential cardiovascular transaction will reduce revenue streams, potentially leaving the company with no commercial products until NXT41X launch, increasing reliance on pipeline success.
- Regulatory clearance for NXT41X is not guaranteed, and any delays in FDA decisions could impact the timeline for commercial launch and revenue generation, despite current on-track expectations.
- The company's focus on NXT41X carries execution risks, including the need to successfully navigate hospital value analysis committees and achieve market adoption, as evidenced by the survey's reliance on surgeon willingness rather than actual purchase commitments.
Good day and thank you for standing by. Welcome to the Elutia Q2 2026 financial results conference call. At this time, all participants are in a listen-only mode.
(Operator instructions)
Please be advised that today's conference isd being recorded. I would now like to hand the conference over to your speaker today, Bernadine Cherniak. Please go ahead.
Thank you, operator, and thank you all for participating in today's call. Earlier today, Alusha released financial results for the second quarter ended June 30, 2026. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1,995.
Any statements contained in this call that do not relate to matters of historical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
